PNB-281 first human dosing
Peptinovo identifies PNB-281 as its PALM paclitaxel nanomedicine candidate and announced Australian authorization for clinical testing in January 2026. Authorization and actual administration are separate milestones.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- The January 2026 company announcement explicitly calls Peptinovo privately held; recheck before activation.
- Verify whether first dosing already occurred after the authorization announcement; formulation and trial identity require explicit rules.
- Research candidate, not a live market, clinical probability, company equity or access to private shares.
Primary evidence
Clinical-start candidate — current dosing status unconfirmed
Company context
An official company source identifies the company as privately held. This is source-reported context, not independent legal-registry verification; recheck ownership, listing and acquisition status before any market listing.
Potential outcome market
Will a participant receive PNB-281 in its authorized first-in-human trial by the market deadline?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.